Biologic Intraocular Stent Shaping to Reduce Tissue Damage

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current ab interno stenting devices for glaucoma treatment using non-biological hardware materials cause erosion and fibrosis, leading to ocular tissue damage such as endothelial cell loss.

Innovation Solution

A system and method for preparing and inserting a biologically-derived implant using a tissue cartridge, cutting device, and delivery device, which minimally modifies biological tissue to form a stent for ab interno insertion, providing a biocompatible aqueous outflow pathway.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If non-biological hardware materials are used for ab interno stenting devices, then the structural strength and durability of the implant is improved, but tissue damage such as erosion, fibrosis and endothelial cell loss occurs

Engineering Contradiction:

Improvestructural strengthVSAvoidtissue damage

Core Design Contradiction:

StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent changes the material parameter from non-biological hardware to biologically-derived materials (such as collagen, elastin, or other natural polymers). This material substitution maintains the necessary structural strength for the stent to function while eliminating the harmful tissue damage effects associated with non-biological materials, as the biological materials are naturally integrated by the body without causing erosion or fibrosis

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention employs composite material structures that combine biological materials with appropriate structural configurations. The stent is formed from biologically-derived materials that provide both mechanical strength and biocompatibility, creating a composite solution that satisfies both the strength requirement and the harm reduction requirement

Inventive Principle:

Principle #40Composite materials

2Object-affected harmful factors

If biologically-derived materials are used for stent implants, then biocompatibility and reduced tissue damage are improved, but manufacturing complexity and material availability challenges arise

Engineering Contradiction:

ImprovebiocompatibilityVSAvoidmanufacturing complexity

Core Design Contradiction:

Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The patent utilizes biologically-derived materials that can be obtained through standardized biological sources and processing methods. By employing materials like collagen and elastin that have established supply chains and processing protocols, the invention reduces manufacturing complexity compared to custom biological tissue fabrication, while maintaining the biocompatibility benefits

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The invention standardizes the material parameters by selecting specific biologically-derived materials with well-defined properties. By specifying particular materials (collagen, elastin, or other natural polymers) with known manufacturing protocols, the patent transforms the complexity of working with biological materials into a controlled process that maintains biocompatibility while improving manufacturability

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250275869A1System for shaping and implanting biologic intraocular stent for increased aqueous outflow and lowering of intraocular pressure

Publication Date: 2025.09.04 IANTREK INC

AI summary

Systems and methods for preparation of an implant and for ab interno insertion of the implant into an eye of a patient including a tissue cartridge configured to receive and hold a patch of a material; a cutting device; and a delivery device. Related devices, systems, and methods are provided.